Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE: Surufatinib and Serplulimab in Pancreatic Cancer
NCT05988372Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2023
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, serplulimab in pancreatic cancer (PC), sponsored by Sun Yat-sen University. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
surufatinibserplulimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05988372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988372.